Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: A prospective patient cohort study

Breast Cancer Research

Volumn 13, Issue 4, 2011, Pages

  Vrieling, Alina ^a   Hein, Rebecca ^a   Abbas, Sascha ^b   Schneeweiss, Andreas ^c   Flesch Janys, Dieter ^d   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; TAMOXIFEN; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; VITAMIN D;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONCENTRATION RESPONSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHYSICAL ACTIVITY; POSTMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; VITAMIN BLOOD LEVEL; BLOOD; BREAST TUMOR; GERMANY; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

AGED; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; VITAMIN D;

EID: 79960679971     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2920     Document Type: Article

References (23)

1. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010, 46:2196-2205. 10.1016/j.ejca.2010.03.037, 20456946.
2. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009, 94:26-34. 2630868, 18854395.
3. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009, 19:73-78. 10.1016/j.annepidem.2007.12.001, 2665033, 18329892.
4. Gorham ED, Garland CF, Garland FC. Acid haze air pollution and breast and colon cancer mortality in 20 Canadian cities. Can J Public Health 1989, 80:96-100.
5. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990, 19:614-622. 10.1016/0091-7435(90)90058-R, 2263572.
6. Grant WB, Mohr SB. Ecological studies of ultraviolet B, vitamin D and cancer since 2000. Ann Epidemiol 2009, 19:446-454. 10.1016/j.annepidem.2008.12.014, 19269856.
7. Robsahm TE, Tretli S, Dahlback A, Moan J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004, 15:149-158.
8. Porojnicu AC, Lagunova Z, Robsahm TE, Berg JP, Dahlback A, Moan J. Changes in risk of death from breast cancer with season and latitude: sun exposure and breast cancer survival in Norway. Breast Cancer Res Treat 2007, 102:323-328. 10.1007/s10549-006-9331-8, 17028983.
9. Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P, Møller H. Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer 2006, 119:1530-1536. 10.1002/ijc.22052, 16671100.
10. Palmieri C, MacGregor T, Girgis S, Vigushin D. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol 2006, 59:1334-1336. 10.1136/jcp.2006.042747, 1860540, 17046848.
11. Neuhouser ML, Sorensen B, Hollis BW, Ambs A, Ulrich CM, McTiernan A, Bernstein L, Wayne S, Gilliland F, Baumgartner K, Baumgartner R, Ballard-Barbash R. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 2008, 88:133-139. 2997620, 18614733.
12. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009, 27:3757-3763. 10.1200/JCO.2008.20.0725, 19451439.
13. Jacobs ET, Thomson CA, Flatt SW, Al-Delaimy WK, Hibler EA, Jones LA, Leroy EC, Newman VA, Parker BA, Rock CL, Pierce JP. Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. Am J Clin Nutr 2011, 93:108-117. 10.3945/ajcn.2010.30009, 20980485.
14. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008, 123:933-941. 10.1002/ijc.23655, 18506692.
15. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknaus EJ, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study. Carcinogenesis 2008, 29:93-99.
16. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007, 25:2127-2132. 10.1200/JCO.2006.10.3523, 17513820.
17. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999, 28:964-974. 10.1093/ije/28.5.964, 10597998.
18. Santini D, Galluzzo S, Vincenzi B, Zoccoli A, Ferraro E, Lippi C, Altomare V, Tonini G, Bertoldo F. Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 2010, 21:185-186. 10.1093/annonc/mdp497, 19892747.
19. Kailajarvi ME, Salminen EK, Paija OM, Virtanent AM, Leino AE, Irjala KA. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res 2004, 24:1271-1274.
20. Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009, 27:2151-2156. 10.1200/JCO.2008.19.6162, 2674001, 19349547.
21. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions Vitamin D pathways unbalanced in breast lesions. BMC Cancer 2010, 10:483. 10.1186/1471-2407-10-483, 2945944, 20831823.
22. Lagunova Z, Porojnicu AC, Grant WB, Bruland O, Moan JE. Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association?. Mol Nutr Food Res 2010, 54:1127-1133.
23. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol 2008, 26:2984-2991. 10.1200/JCO.2007.15.1027, 18565885.